Our Milestones

2020

IPO in Shanghai Stock Exchange. Stock Code SH.603392

2019

Innovax received New Drug Certificate for Cecolin® Recombinant HPV Vaccine. Urine HIV self-test launched in China.

2012

Hecolin® awarded the Most Innovative Asian Biotech Excellence Award at the 6th World Vaccine Congress Asia in Singapore

2011

Innovax received New Drug Certificate for Hecolin®

2011

The Phase III Clinical Trial Research Team working on the Hepatitis E vaccine was awarded “Excellent Team of National Science and Technology Program” in the 11th five-year plan period by the Ministry of Science and Technology, China

2011

Innovax set up a new department for the development of integrated diagnostic instruments and Point of Care Testing (POCT) devices and reagent kits

2011

Innovax obtained ‘Excellent Product’ Certificate at 13th China Hi-Tech Fair

2010

Innovax awarded 2nd Prize of National Award for Technological Invention

2010

Hepatitis E Vaccine Phase III study published in The Lancet and Hepatology

2008

Xiamen YST Bio-tech Co., Ltd. was formally merged with Beijing Wantai and renamed as Xiamen Innovax Biotech Co., Ltd.(lnnovax)

2006

China Torch Program supports recombinant Hepatitis E vaccine

2005

Xiamen YST Bio-tech Co., Ltd. was founded by YST with a focus on research and development/commercialization

2001

YST acquired Beijing Biological Pharmacy Enterprise Co., Ltd. (Wantai)

2000

YST invested in and set up Joint Bio Pharmacy R&D Center with Xiamen University

1993

YangShengTang Group (YST) founded by Shanshan Zhong

2020 - Wantai BioPharm. All Rights Reserved. Designed & Developed by SweeneyVesty Studio